How I Treat Patients with MDS Who Have Been Failed by Hypomethylating Agents


The hypomethylating agents (HMAs) azacitidine and decitabine are the most utilized therapies for higher risk patients with myelodysplastic syndromes as well as for a proportion of lower risk patients requiring more intensive therapies. Unfortunately, there remains a significant proportion of these patients who do not respond (primary failure) or lose their response (secondary failure) and require additional therapies to control their disease. Recently, there have been a number of clinical investigations to determine patient populations more or less likely to HMAs as well as experimental therapies designed for this setting. Dr. DeZern will discuss combination therapies, second line options, and novel therapies at the time of HMA failure, as well as the role of more intensive therapy as a bridge to potential stem cell therapy.


  • Amy E. DeZern


Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top